Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gross Profit: 2020-2025

Historic Gross Profit for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $139,000.

  • Insight Molecular Diagnostics' Gross Profit rose 178.00% to $139,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 8503.57%. This contributed to the annual value of $740,000 for FY2024, which is 79.18% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Gross Profit is $139,000, which was down 60.29% from $350,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Gross Profit high stood at $2.6 million for Q4 2021, and its period low was -$866,000 during Q3 2021.
  • Its 3-year average for Gross Profit is $269,727, with a median of $139,000 in 2025.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 1,782.61% in 2021, then skyrocketed by 2,844.44% in 2025.
  • Insight Molecular Diagnostics' Gross Profit (Quarterly) stood at $2.6 million in 2021, then plummeted by 101.04% to -$27,000 in 2022, then crashed by 333.33% to -$117,000 in 2023, then spiked by 608.55% to $595,000 in 2024, then soared by 178.00% to $139,000 in 2025.
  • Its Gross Profit was $139,000 in Q3 2025, compared to $350,000 in Q2 2025 and $1.3 million in Q1 2025.